Table 1.
Characteristics of the study group.
| Female (n = 7) | Male (n = 6) | z | p-Value * | Total | |||||
|---|---|---|---|---|---|---|---|---|---|
| Median (Range) | IQR/2 | Median (Range) | IQR/2 | Median (Range) | IQR/2 | CV% | |||
| Age at T0 (y) | 58.0 (26.0–78.0) |
13.5 | 49.5 (25.0–73.0) |
6.0 | 0.930 | 0.366 | 52.0 (25.0–78.0) |
9.0 | 31.8 |
| Age at Tend (y) | 60.0 (28.0–80.0) |
13.5 | 52.5 (28.0–75.0) |
6.0 | 0.863 | 0.366 | 55.0 (28.0–80.0) |
8.5 | 29.9 |
| Predrug duration of HPN (mo.) |
57.0 (20.0–127.0) |
37.0 | 57.0 (20.0–161.0) |
67.0 | 0.000 | 0.945 | 57.0 (20.0–161.0) |
37.0 | 67.0 |
| Duration of TED treatment (mo.) |
30.0 (25.0–37.0) |
0.5 | 36.0 (25.0–37.0) |
3.0 | −0.878 | 0.366 | 31.0 (25.0–37.0) |
3.0 | 13.3 |
IQR/2: semi-quartile range, CV: coefficient of variation. * Mann–Whitney U test with continuity correction.